Scholars Central

Conference abstractPublished 4 Apr 2022

Development of a novel filtered-based pharmacophore for the identification of human equilibrative nucleoside transporter 1 inhibitors

Authors: Azza Ramadan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: The human equilibrative nucleoside transporters (hENTs) are important transporters that allow nucleosides and nucleobases permeation into the cell. hENT 1 is a promising target against heart and Huntington’s diseases as its inhibition mediates cardiac- and neural protection effects, respectively. However, the current hENT1 inhibitors have significant off-target effects and poor pharmacological profile. Hence there is a need for new novel inhibitors. Methodology: Therefore, we developed a computational protocol for developing ligand-based pharmacophores that identify and select inhibitors of hENT1 in an efficient and specific manner. To examine the efficacy of the pharmacophore and its application later on in the drug discovery of new hENT1 inhibitors, we used this pharmacophore as a filter prior to a small-scale virtual screening (VS) of a drug-like ligand library. The library consisted of 5000 compounds; 56 of which were known hENT1 inhibitors. Findings: First, several pharmacophores were created using a set of known inhibitors. Among the several created pharmacophores, the best inhibitor pharmacophore exhibited high selectivity and specificity rates of 92% and 88%, respectively. Furthermore, another pharmacophore was validated for the oppositely acting type of the hENT1 molecules (i.e. permeants) to act as an extra refinement step in our search for hENT1 inhibitors. Interestingly, employing the inhibitor pharmacophore as a filter-in along with the permeant pharmacophore as a filter-out resulted in up to twofold enhancement of docking-based virtual screening results (see Table 1). Conclusion & Significance: This in silico approach can prove very useful in the discovery of new cardio- and neuroprotective hENT1 inhibitors.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalNanotechnology Letters
  • SubjectNanotechnology
  • BylineArticles whose byline prints “Azza Ramadan”